Cited 29 times in
Understanding the complications of anti-tumor necrosis factor therapy in East Asian patients with inflammatory bowel disease
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 천재희 | - |
dc.date.accessioned | 2017-11-02T08:13:04Z | - |
dc.date.available | 2017-11-02T08:13:04Z | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 0815-9319 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/154211 | - |
dc.description.abstract | Remarkable advances have been made in the treatment of inflammatory bowel disease since the introduction of anti-tumor necrosis factor-α agents, especially for patients who are refractory to or cannot tolerate conventional therapies. Currently, infliximab, adalimumab, and golimumab are available in the East Asian medical market, and these agents have been shown to be effective for inducing and maintaining long-term remission of inflammatory bowel disease. Despite their clinical benefits, anti-tumor necrosis factor therapy can also lead to increased vulnerability to infections, development of autoimmune diseases and malignancy, and decreased immunogenicity of vaccinations. Because infectious diseases, such as tuberculosis, hepatitis, and influenza, remain major health problems in East Asia, more cautious use of biologics is needed. To further improve treatment efficacy and safety, close monitoring of inflammation, regular surveillance for malignancy, and regularly scheduled vaccinations are needed. Treatment strategies for biologics should be customized to meet the needs of different patients. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Blackwell Scientific Publications | - |
dc.relation.isPartOf | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adalimumab/adverse effects* | - |
dc.subject.MESH | Adalimumab/pharmacology | - |
dc.subject.MESH | Adalimumab/therapeutic use* | - |
dc.subject.MESH | Anti-Inflammatory Agents/adverse effects* | - |
dc.subject.MESH | Anti-Inflammatory Agents/pharmacology | - |
dc.subject.MESH | Anti-Inflammatory Agents/therapeutic use* | - |
dc.subject.MESH | Antibodies, Monoclonal/adverse effects* | - |
dc.subject.MESH | Antibodies, Monoclonal/pharmacology | - |
dc.subject.MESH | Antibodies, Monoclonal/therapeutic use* | - |
dc.subject.MESH | Asian Continental Ancestry Group | - |
dc.subject.MESH | Autoimmune Diseases/etiology | - |
dc.subject.MESH | Far East | - |
dc.subject.MESH | Gastrointestinal Agents/adverse effects* | - |
dc.subject.MESH | Gastrointestinal Agents/pharmacology | - |
dc.subject.MESH | Gastrointestinal Agents/therapeutic use* | - |
dc.subject.MESH | Hepatitis, Viral, Human/etiology | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Infection/etiology | - |
dc.subject.MESH | Inflammatory Bowel Diseases/drug therapy* | - |
dc.subject.MESH | Infliximab/adverse effects* | - |
dc.subject.MESH | Infliximab/pharmacology | - |
dc.subject.MESH | Infliximab/therapeutic use* | - |
dc.subject.MESH | Neoplasms/etiology | - |
dc.subject.MESH | Remission Induction | - |
dc.subject.MESH | Tuberculosis/etiology | - |
dc.subject.MESH | Tumor Necrosis Factor-alpha/antagonists & inhibitors* | - |
dc.title | Understanding the complications of anti-tumor necrosis factor therapy in East Asian patients with inflammatory bowel disease | - |
dc.type | Article | - |
dc.publisher.location | Australia | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Internal Medicine | - |
dc.contributor.googleauthor | Jae Hee Cheon | - |
dc.identifier.doi | 10.1111/jgh.13612 | - |
dc.contributor.localId | A04030 | - |
dc.relation.journalcode | J01417 | - |
dc.identifier.eissn | 1440-1746 | - |
dc.identifier.pmid | 27723166 | - |
dc.identifier.url | http://onlinelibrary.wiley.com/doi/10.1111/jgh.13612/abstract | - |
dc.subject.keyword | Crohn's disease | - |
dc.subject.keyword | East Asia | - |
dc.subject.keyword | anti-TNF therapy | - |
dc.subject.keyword | complications | - |
dc.subject.keyword | inflammatory bowel disease | - |
dc.subject.keyword | ulcerative colitis | - |
dc.contributor.alternativeName | Cheon, Jae Hee | - |
dc.contributor.affiliatedAuthor | Cheon, Jae Hee | - |
dc.citation.title | Journal of Gastroenterology and Hepatology | - |
dc.citation.volume | 32 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 769 | - |
dc.citation.endPage | 777 | - |
dc.identifier.bibliographicCitation | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol.32(4) : 769-777, 2017 | - |
dc.date.modified | 2017-11-01 | - |
dc.identifier.rimsid | 42180 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.